周  倩  博士 副研究员 博士生/硕士生导师

邮 箱：zhouqian@hainanu.edu.cn

1.教育背景

2017.08—2022.06，中山大学， 药物化学，理学博士；

2013.08—2017.06，中山大学， 药学，理学学士；

2.科研情况

课题组以磷酸二酯酶为靶标，结合海南丰富独特的黎药与海洋药物资源，进行新型PDE小分子抑制剂开发、适应症探索以及机制研究。目前已在Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, J. Enzym. Inhib. Med. Chem.等SCI期刊发表论文20余篇，其中以通讯/第一作者发表文章10余篇。申请专利10余项，其中授权8项。

3. 研究方向

靶向神经炎症的抗神经退行性疾病的创新药物研究

靶向PDE的抗纤维化药物发现与分子机制研究

4. 项目

[1] 国家自然科学基金委员会，青年科学基金项目，2024-01至2026-12，在研，主持

[2] 海南大学科研启动基金项目，2022-11至2027.11，在研，主持

[3] 海南省自然科学基金面上项目，2024.01.01-2026.12.31，主持

5. 代表性成果

[1] Zhexin Chen^#, Yuqing Shi^#, Fang Zhong, Kai Zhang, Furong Zhang, Shenghong Xie, Zhongbin Cheng, Qian Zhou*, Yi-You Huang*, Hai-Bin Luo*. Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects[J]. Chinese Chemical Letters, 2025, 36(4): 109956.

[2] Yi-You Huang^#, Xiang Luo^#, Kai Zhang^#, Yulan Liang, Furong Zhang, Guochao Liao, Shenghong Xie, Pei-Luo Huang, Siyu Hou, Qian Zhou*, Yong Zou*, Hai-Bin Luo*. Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects[J]. Chinese Chemical Letters, 2024, Doi: 10.1016/j.cclet. 2024.110586.

[3] Mei-Yan Jiang, Chen Zhang, Qing-Hua Huang, Ling-Ling Feng, Yi-Yi Yang, Qian Zhou*, Hai-Bin Luo*, Yinuo Wu*. Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal Pocket[J]. Journal of Medicinal Chemistry, 2024, 67(22): 20203-20213.

[4] Sen Wang ^#, Guofeng Yang ^#, Kai Zhang ^#, Zhexin Chen, Meiying Qiu, Siyu Hou, Tiansheng Zheng, Zongmin Wu, Qinjiang Ma, Furong Zhang, Ge Gao, Yi-You Huang, Qian Zhou*, Hai-Bin Luo*, Deyan Wu*. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis[J]. Bioorganic Chemistry, 2024, 149, 107474.

[5] Qian Zhou^#, Mei-Ling Le ^#, Yiyi Yang, Wenjuan Wang, Yuqi Huang, Quan Wang, Yijing Tian, Meiyan Jiang, Yong Rao*, Hai-Bin Luo*; Yinuo Wu*; Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis, Acta Pharmaceutica Sinica B, 2023. 13(3): 1180-1191.

[6] Qian Zhou^#, Wei-Hao Luo^#, Bei Zhang^#, Zhao-Hang Xue, Qing-Hua Huang, Ling-Ling Feng, Yinuo Wu*, Chen Zhang*. Design, synthesis, and evaluation of quinolin-2(1H)-ones as PDE1 inhibitors for the treatment of inflammatory bowel disease[J]. Bioorganic Chemistry, 2025, 154:107979.

[7] Xu-Nian Wu^#, Qian Zhou^#, Ya-Dan Huang, Xi Xie, Zhe Li, Yinuo Wu, Hai-Bin Luo^*. Structure-Based Discovery of Orally Efficient Inhibitors via Unique Interactions with H-pocket of PDE8 for the Treatment of Vascular Dementia[J]. Acta Pharmaceutica Sinica B, 2022, 12(7): 3103-3112.

[8] Yuncong Yang^#, Sirui Zhang^#, Qian Zhou^#, Chen Zhang, Yuqi Gao, Hao Wang, Zhe Li, Deyan Wu, Yinuo Wu, Yi-You Huang*, Lei Guo*, Hai-Bin Luo*. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension[J]. Acta Pharmaceutica Sinica B, 2020, 10(12): 2339-2347.

[9] Yadan Huang^#, Xu-Nian Wu^#, Qian Zhou^#, Yinuo Wu, Dongxiao Zheng, Zhe Li, Lei Guo, Hai-Bin Luo^*. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors[J]. Journal of Medicinal Chemistry, 2020, 63(24):15852-15863.

[10] Jinhao Liang^#, Yi-You Huang^#, Qian Zhou^#, Yuqi Gao, Zhe Li, Deyan Wu, Si Yu, Lei Guo, Zhen Chen, Ling Huang, Steven H Liang, Xixin He^*, Ruibo Wu^*, Hai-Bin Luo^*. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia[J]. Journal of Medicinal Chemistry, 2020, 63(6): 3370–3380.

[11] Yinuo Wu^#, Qian Zhou^#, Tianhua Zhang^#, Zhe Li, Yi-Ping Chen, Pei Zhang, Yan-Fa Yu, Haiju Geng, Yi-Jing Tian, Chen Zhang, Yu Wang, Jian-Wen Chen*, Yan Chen*, Hai-Bin Luo*. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia[J]. Journal of Medicinal Chemistry, 2019, 62:4218-4224.

[12] Mei-Ling Le, Yi-Yi Yang, Mei-Yan Jiang, Chuan Han, Zhi-Rong Guo, Run-Duo Liu, Zheng-Jiong Zhao, Qian Zhou*, Shijun Wen*, Yinuo Wu*. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia[J]. Bioorganic Chemistry, 2024, 144:107114.

[13] Chen Zhang^#, Qian Zhou ^#, Xu-Nian Wu, Ya-Dan Huang, Jie Zhou, Zengwei Lai^*, Yinuo Wu^*, Hai-Bin Luo. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33(1):260-270.

[14] 周倩, 侯思宇, 罗海彬, 郇婉婷, 张锴, 谢圣弘. 用于降低尿酸水平的磷酸二酯酶5型抑制剂及其用途, 2024-05-28,中国, 118079003A.

[15] 罗海彬, 周倩, 侯思宇, 郇婉婷, 张锴. 降低尿酸和/或预防尿酸升高的中药及其制备方法和应用, 2024-05-28,中国, 118078872A.

[16] 罗海彬, 周倩, 卢明伟, 侯思宇, 张锴, 吴德燕. 预防和/或治疗高尿酸血症的中药复方及制备方法和应用, 2024-07-19, 中国, 118356448A .

[17]罗海彬; 吴旭年; 黄雅丹; 周倩; 一种2-氯腺嘌呤衍生物、制备方法及应用, 2022-03-25, 中国, CN202011126602.3.

[18]罗海彬; 黄仪有; 李哲; 周倩; 托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用, 2022-02-01, 中国, CN202010105310.5.

[19]罗海彬; 吴一诺; 张佩; 周倩; 陈仪萍; 张天华; 于艳发; 吴旭年; 一类N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用, 2021-05-14, 中国, CN201810858465.9.